Clear-cell carcinomas are some of the most common renal cancers observed in humans. Current medical efforts at finding cures to the cancer focus on the responses of it to the inhibition of RAF-1, VEGR and PDGFR, all found in the Caki-1 cell line. Through transfection experiments with appropriate reagents, researchers can examine the possibilities of genetic modification and its ramifications on the physiology of Caki-1, leading to reliable results that can inform preclinical trials and commercial drug development.
The Caki-1 cell line was established from the renal carcinoma cells of a 49-year-old male patient with clear cell carcinoma. Caki-1 cells contain many microvilli, small mitochondria,and well developed endoplasmic reticulum (ER) and golgi apparatus. This cell line is not commercially available and is only available for research purposes. Transfection of the Caki-1 cell is facilitated by Caki-1 transfection reagents ( Altogen biosystems ) to establish stable cell lines, produce consistent research and to optimize transfection of siRNA, miRNA and pDNA. Caki-1 Transfection Reagent (Kidney Epithelial Cells)
Comments
Post a Comment